A Phase 2 interventional study of Amimestrocel in Diabetic Kidney Disease (DKD), sponsored by Chinese PLA General Hospital. Recruiting at 6 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by Chinese PLA General Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Diabetic Nephropathies with a site in China — 22 open to participants now, 30 under way, none of them phase 3. Diabetic Nephropathies · China.
Among the 75 studies in Diabetic Nephropathies with a site in China, this one is the 27th largest by planned enrollment of the 52 interventional ones that give a count, is one of 7 that started in 2025, is one of 7 in phase 2, reaches primary completion later than 14 of the 29 other live ones, and was the 65th registered.
544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.
Browse Diabetic Nephropathies studies →22 of the 75 studies in Diabetic Nephropathies with a site in China are open now. Recruiting first, the newest first:
Huijie Zhang · Sites in China
Ages 18–70
Tongji Hospital · Sites in China
Ages 30–70
Alebund Pharmaceuticals · Sites in China
Ages 30+
Shengjing Hospital · Sites in China
Ages 18–80 · Healthy volunteers
Chinese PLA General Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 6 · Phase 4 11
First in 2003; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 78 across 389 interventional studies indexed under Diabetic Nephropathies.
Median enrollment 122 across the 52 interventional studies, 620 across the 22 observational. Of the 29 that completed or were terminated, 6 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 75 have an industry lead sponsor. The 10 most frequent:
Chinese PLA General Hospital is the lead sponsor of 574 studies on the registry; 209 are open to participants now.
Chinese PLA General Hospital has 6 studies filed under Diabetic Nephropathies — fewer than ten, so there is no comparison to draw.
4 of the studies in Diabetic Nephropathies with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05349955Shanghai Zhongshan HospitalEffects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community | 2026-11-30 |
| NCT06843304Chinese PLA General HospitalThe Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy | 2026-12 |
| NCT06452862Shengjing HospitalMultimodal Magnetic Resonance Imaging in Evaluation of Diabetic Kidney Disease | 2027-06-06 |
| NCT03865914Chinese PLA General HospitalCorrelation Study Between Clinical Phenotype and Pathology of Type 2 Diabetic Nephropathy | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 75 studies in Diabetic Nephropathies with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is to evaluate the efficacy and safety of umbilical cord-derived mesenchymal stromal cells (Amimestrocel ) in study subjects with progressive diabetic kidney disease (DKD), to investigate whether Amimestrocel can improve renal function or proteinuria of DKD patients.
Inclusion Criteria: -
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients receive standard treatment and Amimestrocel is administered via Intravenous infusion on day 1, 14, 28, and week 8, 12, 16, 20, 24.
Drug: Amimestrocel
In the first month (day 1, 14, 28): 1×10\^6 cells per kilogram. From the 8th to the 24th week (week 8, 12, 16, 20, 24): 1.5×10\^6 cells per kilogram.
Urine protein
Urine protein will be measured on 24h urine samples
Time frame: Change from baseline at 24 weeks
estimated Glomerular Filtration Rate(eGFR)
GFR will be estimated by CKD-EPI
Time frame: Change from baseline at 24 weeks
fasting blood glucose
fasting blood glucose
Time frame: Change from baseline at 24 weeks and then every 6 months to study completion, up to 24 months after cell infusion
HbA1c
Glycated Hemoglobin A1c
Time frame: Change from baseline at 24 weeks and then every 6 months to study completion, up to 24 months after cell infusion
Urinary Albumin/Creatinine Ratio(UACR)
UACR will be measured on spot morning urine samples
Time frame: Change from baseline at 24 weeks and then every 6 months to study completion, up to 24 months after cell infusion
proportion of outcome ( ≥50% declined in eGFR,reached end stage renal disease (ESRD), or occured Renal replacement)
proportion of outcome ( ≥50% declined in eGFR,reached End Stage Renal Disease (ESRD), or occured Renal Replacement Therapy)
Time frame: proportion of study participants within outcome at 24 weeks and then every 6 months to study completion, up to 24 months after cell infusion
proportion of major adverse cardiac events(MACE) and all-cause mortality
proportion of major adverse cardiac events(MACE:CV death, non-fatal CV event(myocardial infarction, stroke, hospitalization for HF)) and all-cause mortality
Time frame: proportion of study participants within outcome at 24 weeks and then every 6 months to study completion, up to 24 months after cell infusion
Mechanism exploration
Explore the mechanism through blood tests(Serum/plasma concentrations (pg/ml) of biomarkers of inflammation. Proportion/total number of circulating T cells, B cells, NK cells, etc ).
Time frame: Change from baseline at 4,12,24 weeks and 12 months
changes in retinal imaging
Macular vascular density by Optical Coherence Tomography Angiography (OCTA), and analyze the percentage of changes in retinal imaging of patients compared to the baseline .
Time frame: Change from baseline at 24 weeks and then every 6 months to study completion, up to 24 months after cell infusion
Changes in peripheral nerve injury
Examine through electromyography, to evaluate the percentage of changes in peripheral nerve injury of patients compared with the baseline.
Time frame: Change from baseline at 24 weeks and then every 6 months to study completion, up to 24 months after cell infusion
Changes in symptoms
The traditional Chinese Medicine(TCM)Syndrome Rating Scale will be used to score TCM symptoms,to evaluate the percentage of changes in the symptoms of patients compared with the baseline.
Time frame: Change from baseline at 24 weeks and then every 6 months to study completion, up to 24 months after cell infusion
Changes in the quality of life scale
The Diabetes Quality-of-Life Measure (DQOL) will be used to score quality of life at each visit, to evaluate the percentage of the change in the DQOL of patients compared to the baseline
Time frame: Change from baseline at 24 weeks and then every 6 months to study completion, up to 24 months after cell infusion
Adverse Event and Serious Adverse Event(SAE)
Time frame: within 28 weeks after received Amimestrocel
secondary malignant disease
Number of Participants with secondary malignant disease
Time frame: within 24 months after received Amimestrocel
Started Jun 2025 (actual). Primary completion is estimated for Aug 2026, 14 months after the start.
Of 52 phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's planned 14 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese PLA General Hospital →